



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

CAPEcitabine (Xeloda®)



* X E L - 0 0 0 0 0 - 0 3 - C N - M L *



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Recurrent/Advanced stage/Metastatic colorectal cancer.

Recurrent/Advanced stage/Metastatic breast cancer.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC \geq 1000; HB \geq 80; Plt \geq 100,000; CrCl $>$ 45 ml/min.

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
CAPEcitabine	1000 - 1250 mg/mg ² PO bid	To be taken With water within 30 min of a meal.	D1 - 14
To be repeated every 3 weeks, usually for 6 - 8 cycles but can be continued until disease progression or intolerable toxicity.			

Treatment Description:

Cycle	Day	Date	CAPEcitabine	Physician	Consultant
C# __	D1 - 14				
C# __	D1 - 14				
C# __	D1 - 14				
C# __	D1 - 14				
C# __	D1 - 14				
C# __	D1 - 14				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for \geq 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No